Lurbinectedin is a drug that is used to treat certain types of cancer. According to the sources provided, it is not effective against all cancers.

Lurbinectedin is a chemotherapy drug that works by inhibiting the transcription of DNA. It has been approved by the FDA for the treatment of small cell lung cancer (SCLC) that has progressed after initial treatment [1]. In a study published in the Journal of Clinical Oncology, lurbinectedin was found to be effective in treating relapsed SCLC, with a response rate of 35% [3].

However, the drug has not been approved for the treatment of other types of cancer. According to the Drug Patent Watch website, lurbinectedin is only indicated for the treatment of SCLC [1].

In addition, the cost-effectiveness of lurbinectedin has been evaluated specifically for its use as a second-line treatment for SCLC. A study published in Targeted Oncology found that lurbinectedin was cost-effective as a second-line treatment for SCLC, but the study did not evaluate the drug's effectiveness against other types of cancer [2].

Therefore, based on the sources provided, lurbinectedin is not effective against all cancers. It is only approved for the treatment of relapsed SCLC and has not been evaluated for use in other types of cancer.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Targeted Oncology. Lurbinectedin Is Cost-Effective as a Second-Line Treatment in SCLC. Retrieved from https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] Trigo, J., Subbiah, V., Besse, B., et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Journal of Clinical Oncology. 2020; 38(9): 876-884. doi: 10.1200/JCO.19.02646.